Skip to main content
U.S. flag

An official website of the United States government

2018 NIH Alzheimer's Disease Research Summit

N I H Alzheimer's Disease Research Summit 2018: Path to Treatment and Prevention. March 1-2 2018, Bethesda, MD.

Recommendations from 2018 Summit (5/25/2018)

View videocast of 2018 Summit:

Participant Biographies

List of 2018 AD Summit Sponsors


The NIH AD Research Summits are key strategic planning meetings tied to the implementation of the first goal of the National Plan to Address Alzheimer's: to treat and prevent Alzheimer's disease by 2025. They bring together a multi-stakeholder community including government, industry, academia, private foundations, and patient advocates to formulate an integrated, translational research agenda that will enable the development of effective therapies (disease modifying and palliative) across the disease continuum for the cognitive as well as neuropsychiatric symptoms of Alzheimer's disease.

The 2012 and 2015 AD Research Summits delivered recommendations that served as the basis for developing research implementation milestones detailing specific steps and success criteria for the NIH and other stakeholders towards the development of effective treatment and prevention for AD. The milestones span the entire AD research landscape including basic, translational, clinical and health services research and serve as the basis for the development of the NIH Alzheimer's Disease Bypass Budget.

Goal: The 2018 Summit will build on the foundation laid by the NIH AD Research Summits held in 2012 and 2015. It will feature progress towards achieving the AD research implementation milestones and to continue the development of an integrated multidisciplinary research agenda necessary to enable precision medicine for AD. Key to achieving this goal is the identification of: 1) resources/infrastructure and multi-stakeholder partnerships necessary to successfully implement this research agenda and 2) strategies to engage patients, caregivers, and citizens as direct partners in research.

Program Structure: The central programmatic themes of the 2018 Summit are: 1) understanding disease heterogeneity, 2) enhancing research rigor, reproducibility, and translatability and 3) enabling rapid translational learning through open science systems and incentives.

The Program agenda will be organized around seven sessions:

  1. Novel Mechanistic Insights into the Complex Biology and Heterogeneity of AD
  2. Enabling Precision Medicine for AD
  3. Translational Tools and Infrastructure to Enable Predictive Drug Development
  4. Emerging Therapeutics
  5. Understanding the Impact of the Environment to Advance Disease Prevention
  6. Advances in Disease Monitoring, Assessment and Care
  7. Building an Open Science Research Ecosystem to Accelerate AD Therapy Development

The program will begin with an overview of progress achieved to date, followed by three plenary lectures. Each of the seven sessions will feature up to four brief presentations followed by a moderated discussion that will include 6-9 panelists with diverse expertise. Collectively, the session speakers and panelists will highlight major advances and discuss key issues. The composition of speakers and panelists for each session will include representatives from academia, industry, federal agencies, private foundations and public advocacy groups working on Alzheimer's and other complex diseases.

Outcome: The general program will be followed by a writing session during which a select group of experts together with NIA/NIH staff and representatives from other U.S. AD funding agencies and NAPA Council members will discuss and help finalize the recommendations put forward by the Summit participants. These recommendations will inform research priorities and serve as the basis for updating and refining the NAPA research milestones for measuring progress towards the goal to prevent or treat AD by 2025.


DAY ONE - March 1, 2018

8:00am - 8:10am

  • Opening Remarks
    Francis Collins, Director, NIH

8:10am - 8:30am

  • Introduction to the Summit Program
    Eliezer Masliah, Director, Division of Neuroscience, NIA/NIH
  • AD/ADRD Research Milestones Progress Report
    Richard Hodes, Director, NIA/NIH

8:30am - 9:30am

Plenary Talks:

  • The Role of Public Advocacy in the Global Fight Against Dementia
    Maria Carrillo, Alzheimer's Association
  • Biomedical Research in the Era of Precision Medicine: The All of US Initiative
    Joni Rutter, NIH
  • The Future is Now: Deconstructing Disease Complexity to Enable Precision Medicine for AD
    Eric Schadt, Icahn Institute at Mount Sinai

9:30am - 11:45am

Novel Mechanistic Insights into the Complex Biology and Heterogeneity of AD

Chairs: Nilufer Ertekin-Taner (Mayo Clinic) and Robert Bell (Pfizer)


  • Rediscovering Myelin: From Genetics to Molecular Mechanisms
    Nilufer Ertekin-Taner, Mayo Clinic
  • Novel Insights in the Neuroimmune Etiology of AD
    Joel Dudley, Icahn Institute at Mount Sinai
  • Autophagy: Common Mechanisms in Aging, Cancer and Alzheimer's
    Ana-Maria Cuervo, Albert Einstein College of Medicine
  • Structural Diversity of Pathogenic Proteins: Implications for Therapy Development
    Robert Tycko, NIDDK/NIH


  • Marco Colonna, Washington University
  • Carol Colton, Duke University
  • Elizabeth Bradshaw, Columbia University
  • Stuart Lipton, Scripps Research Institute
  • Lennart Mucke, Gladstone Institute, UCSF
  • Gabriela Chiosis, Memorial Sloan Kettering Cancer Center
  • Ben Wolozin, Boston University
  • Ben Readhead, ASU-Banner Health
  • Robert Bell, Pfizer

MODERATED DISCUSSION: 11:15am - 11:45am

11:45am - 12:45pm LUNCH

12:45pm - 2:45pm

Enabling Precision Medicine for AD

Chairs: David Bennett (Rush University) and Rima Kaddurah-Daouk (Duke University)


  • Integrative Metabolomics: From Target Discovery to Disease Sub-Classification
    Matthias Arnold, Institute for Bioinformatics and Systems Biology, Munich
  • Integrative Proteomics for Novel Target and Biomarker Discovery
    Nick Seyfried, Emory University
  • Translational Epidemiology of Diverse Cohorts
    Rachel Whitmer, Kaiser Division of Research/University of California, San Francisco
  • AD Genetics in the Era of Precision Medicine: Signals from Global Collaborations
    Cornelia van Dujin, Erasmus University Rotterdam


  • Liana Apostolova, Indiana University
  • Nicole Schupf, Columbia University
  • Mariet Allen, Mayo Clinic
  • Nir Barzilai, Albert Einstein School of Medicine
  • Catherine Kaczorowski, Jackson Labs
  • Chris Gaiteri, Rush University
  • Sean Bendall, Stanford University


2:45pm - 4:45pm

Translational Tools and Infrastructure for Predictive Drug Development

Chairs: David Collier (Eli Lilly) and Allan Levey (Emory University)


  • MODEL-AD Consortium: Infrastructure for Next-Gen Animal Models Development and Preclinical Efficacy Testing
    Greg Carter, Jackson Labs
  • Infrastructure and Recruitment for Next-Generation Clinical Trials
    Laurie Ryan, NIA/NIH
  • Deploying QSP Models for Precision Medicine – from Target Validation to Clinical Trial Design
    Cynthia J. Musante, Pfizer


  • Gerard Schellenberg, University of Pennsylvania
  • Nathan Price, Institute for Systems Biology
  • Joel Dudley, Icahn Institute at Mount Sinai
  • Opher Gileadi, Structural Genomics Consortium, Oxford
  • Jacob Hooker, Massachusetts General Hospital
  • Valentina Fossati, New York Stem Cell Foundation
  • Lorenzo Refolo, NIA/NIH


4:45pm - 5:45pm

Emerging Therapeutics Part I

Chairs: Kalpana Merchant (Chaperone Therapeutics) and Rachelle Doody (Roche)


  • Neurotrophic Modulators as a Therapeutic for AD
    Frank Longo, Stanford University
  • Neuro-regenerative Therapeutics for AD
    Roberta Diaz Brinton, University of Arizona
  • PDE4 inhibitors for MCI and AD
    Mark Gurney, Tetra Therapeutics
  • Reinvigorating the Industry Pipeline Through Precompetitive Partnerships
    David Collier, Eli Lilly

5:45pm Adjourn DAY ONE

DAY TWO - May 24, 2018

8:00am - 8:10am

  • Introduction
    Eliezer Masliah, Director, Division of Neuroscience, NIA/NIH

8:10am - 9:30am

Emerging Therapeutics Part II

Chairs: Rachelle Doody (Roche) and Roberta Diaz Brinton (University of Arizona)


  • Neuroregenerative Therapeutics for AD
    Roberta Diaz Brinton, University of Arizona
  • PDE4 Inhibitors for MCI and AD
    Mark Gurney, Tetra Discovery Partners
  • Neurotrophic Modulators as a Therapeutic for AD
    Frank Longo, Stanford University


  • Mark Tuszynski, University of California, San Diego
  • Linda J. Van Eldik, University of Kentucky
  • Daniel Martin Watterson, Neurokine Therapeutics
  • Steven Wagner, University of California, San Diego
  • Michela Gallagher, AgeneBio
  • Rong Xu, Case Western Reserve University
  • Alice Taubes, University of California, San Francisco


9:30am - 11:45am

Understanding the Impact of the Environment to Advance Disease Prevention

Chairs: Laura Baker (Wake Forest School of Medicine) and Chirag Patel (Harvard Medical School)


  • Translating Knowledge about Socioeconomic Risk Factors into Disease Prevention
    Jennifer Manly, Columbia University
  • The Circadian Etiology of AD
    Andrew Lim, University of Toronto
  • Measuring the Impact of Chemical Pollutants on the Brain Across the Lifespan
    Kelly M. Bakulski, University of Michigan
  • Multi-Modal Life-Style Interventions: What Nonpharmacologic Interventions Tell Us About Disease Mechanisms
    Laura Baker, Wake Forest School of Medicine


  • Mariana G. Figueiro, Rensselaer Polytechnic Institute
  • Andrew J. Saykin, Indiana University
  • Rong Xu, Case Western Reserve University
  • Martha Clare Morris, Rush University
  • Aliza P. Wingo, Emory University
  • Noam Beckmann, Icahn Institute at Mount Sinai
  • Gayathri J. Dowling, NIDA/NIH
  • Sumitra Muralidhar, U.S. Department of Veterans Affairs

MODERATED DISCUSSION: 11:15am - 12:00pm

12:00pm - 1:00pm LUNCH BREAK

1:00pm - 3:15pm

Advances in Disease Monitoring, Assessment, and Care

Chairs: Rhoda Au (Boston University) and Daniela Brunner (Early Signal)


  • eHealth Tools to Quantify Brain Health Across the Disease Trajectory
    Rhoda Au, Boston University
  • Digital Tools for Sleep Monitoring and Optimization
    Daniela Brunner, Early Signal
  • Revolutionizing In-Home Disease Monitoring: The CART Initiative
    Jeffrey Kaye, Oregon Health & Science University
  • New Directions in Research on Care: Report from the AD Care Summit
    Katie Maslow, Gerontological Society of America


  • Corinna Lathan, Anthrotronix, Inc.
  • Larsson Omberg, Sage Bionetworks
  • Dorothy Farrar-Edwards, University of Wisconsin, Madison
  • Hiroko H. Dodge, Oregon Health & Science University/University of Michigan
  • Meryl Comer, USAgainstAlzheimer's
  • Ardy Arianpour, Seqster


3:15pm - 3:30pm BREAK

3:30pm - 5:30pm

Building an Open Science Research Ecosystem to Accelerate AD Therapy Development

Chairs: Lara Mangravite (Sage Bionetworks) and Eric M. Reiman (Banner Alzheimer's Institute)


  • Liberating Clinical Trials Data to Enable Translational Learning
    Eric M. Reiman, Banner Alzheimer's Institute
  • Why We Need Open Drug Discovery for AD
    Aled Edwards, University of Toronto
  • Accelerating Reproducible and Translatable Discovery Research through Open Science
    Lara Mangravite, Sage Bionetworks


  • Magali Haas, Cohen Veterans Bioscience
  • Katja Brose, Chan Zuckerberg Initiative
  • Amiee Aloi, bgC3
  • Kevin Da Silva, Nature Publishing Group
  • Jessica Polka, ASAPbio
  • Rachel Harding, University of Toronto
  • Suzana Petanceska, NIA/NIH



An official website of the National Institutes of Health